Brainsway (NASDAQ:BWAY – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $19.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 57.81% from the company’s current price.
BWAY has been the topic of several other research reports. Wall Street Zen upgraded shares of Brainsway from a “hold” rating to a “buy” rating in a research report on Sunday, August 2nd. BTIG Research restated a “buy” rating and set a $20.00 price target on shares of Brainsway in a research report on Thursday, September 10th. Zacks Research lowered shares of Brainsway from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. LADENBURG THALM/SH SH raised their price target on shares of Brainsway from $18.00 to $18.80 and gave the company a “buy” rating in a research report on Thursday, August 13th. Finally, New Street Research restated a “buy” rating on shares of Brainsway in a research report on Friday, July 24th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.20.
Check Out Our Latest Research Report on Brainsway
Brainsway Stock Up 5.2%
Shares of NASDAQ:BWAY traded up $0.60 during midday trading on Monday, reaching $12.04. The company’s stock had a trading volume of 60,353 shares, compared to its average volume of 150,746. The firm has a market capitalization of $484.61 million, a PE ratio of 27.36 and a beta of 1.29. The stock has a fifty day moving average of $13.71 and a 200 day moving average of $14.64. Brainsway has a twelve month low of $7.14 and a twelve month high of $17.40.
Brainsway (NASDAQ:BWAY – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.10 by $0.04. The company had revenue of $17.11 million for the quarter, compared to analyst estimates of $16.54 million. Brainsway had a net margin of 15.65% and a return on equity of 12.74%. Sell-side analysts anticipate that Brainsway will post 0.33 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Brainsway
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Brainsway during the first quarter valued at $40,000. Ballast Advisors LLC purchased a new position in Brainsway during the first quarter valued at $55,000. Royal Bank of Canada lifted its holdings in Brainsway by 84.2% during the first quarter. Royal Bank of Canada now owns 15,490 shares of the company’s stock valued at $206,000 after purchasing an additional 7,080 shares in the last quarter. Bank of America Corp DE purchased a new position in Brainsway during the first quarter valued at $206,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in Brainsway during the first quarter valued at $232,000. 30.11% of the stock is owned by hedge funds and other institutional investors.
About Brainsway
BrainsWay Ltd. is a medical technology company that develops and commercializes noninvasive treatments for brain disorders. Its primary technology, Deep Transcranial Magnetic Stimulation (Deep TMS), uses electromagnetic fields to stimulate targeted areas of the brain and is delivered through specialized treatment systems and helmet-like coils.
The company’s Deep TMS platform is used by healthcare providers in the treatment of major depressive disorder, obsessive-compulsive disorder and smoking addiction, subject to applicable regulatory clearances and local treatment guidelines.
Recommended Stories
- Five stocks we like better than Brainsway
- Luxury’s Middle Market Is Cracking—These 3 Stocks Could Win
- Rate-Resilient vs. Rate-Exposed: Why Homebuilder Stocks Are Diverging
- The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
- 5 Beaten-Down AI Names That Could Bounce If Fear Fades
Receive News & Ratings for Brainsway Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainsway and related companies with MarketBeat.com's FREE daily email newsletter.
